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Post-mastectomy radiotherapyBackground and purpose: Post mastectomy radiotherapy (PMRT) reduces loco-regional recurrence (LRR)
and has been associated with survival beneﬁt. It is recommended for patients with T3/T4 tumours
and/or P4 positive lymph nodes (LN). The role of PMRT in 1–3 positive LN and LN negative patients is
contentious. The C-PMRT index has been designed for selecting PMRT patients, using independent
prognostic factors for LRR. This study reports a 10 year experience using this index.
Materials and methods: The C-PMRT index was constructed using the following prognostic factors (a)
number of positive LN/lymphovascular invasion, (b) tumour size (c) margin status and (d) tumour grade.
Patients were categorised as high (H) risk, intermediate (I) risk and low (L) risk. PMRT was recommended
for H and I risk patients. The LRR, distant metastasis and overall survival (OS) rates were measured from
the day of mastectomy.
Results: From 1999 to 2009, 898 invasive breast cancers in 883 patients were treated by mastectomy (H:
323, I: 231 and L: 344). At a median follow up of 5.2 years, 4.7% (42/898) developed LRR. The 5-year actu-
arial LRR rates were 6%, 2% and 2% for the H, I and L risk groups, respectively. 1.6% (14/898) developed
isolated LRR (H risk n = 4, I risk group n = 0 and L risk n = 10). The 5-year actuarial overall survival rates
were 67%, 77% and 90% for H, I and L risk groups, respectively.
Conclusion: Based on published literature, one would have expected a higher LRR rate in the I risk group
without adjuvant RT. We hypothesise that the I risk group LRR rates have been reduced to that of the L
risk group by the addition of RT. Apart from LN status and tumour size, other prognostic factors should
also be considered in selecting patients for PMRT. This pragmatic tool requires further validation.
Crown Copyright  2014 Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 110 (2014)
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licenses/by-nc-sa/3.0/).Post mastectomy radiotherapy (PMRT) reduces loco-regional
recurrence (LRR) and improves overall survival [1–3]. There is
international consensus to recommend PMRT for patients with
tumour size P5 cm (T3), tumour invasion of the skin, pectoral
muscle or chest wall (T4) and patients with P4 positive lymph
nodes (LN) [4–6]. However, the role of PMRT for patients with
1–3 positive LN and LN negative patients is contentious. Trials
endorsing the use of PMRT for 1-3 positive LN are often criticised
for the use of less intensive chemotherapy and limited axillary dis-
section and the role of radiotherapy in this subgroup of patients’remains unclear [7,8]. An international survey amongst members
of the American Society for Therapeutic Radiology and Oncology
(ASTRO) and the European Society for Therapeutic Radiology and
Oncology (ESTRO) highlighted a 40:60 split opinion amongst
respondents on the role of PMRT for patients with 1–3 positive
LN [9]. Apart from LN status, other prognostic factors for LRR
include tumour grade, lymphovascular invasion (LVI), oestrogen
receptor (ER) status, tumour size and young age, with the risk of
LRR increasing proportionally to the number of adverse prognostic
factors [10–14]. It is unclear on how these prognostic factors
should be used for selecting patients for PMRT.
The need for clinical trials of PMRT for this sub-group of pa-
tients has been recognised as an international priority. The North
American Breast Intergroup trial, set up speciﬁcally to address this
issue, closed prematurely in 2003 due to poor accrual [15]. The
462 Patient selection for post-mastectomy RTEuropean SUPREMO trial has completed recruitment to investigate
the effects of PMRT on LRR, overall survival (OS) and quality of life
for this group of patients. However, it will take some years before
any conclusive results become available [16]. In 1999, a practical
index was designed at the Cambridge Breast Unit (CBU) for select-
ing patients for PMRT. The Cambridge post-mastectomy
radiotherapy (C-PMRT) index is based on patient’s LN status and
other prognostic factors for LRR. This study reports a 10 year expe-
rience of using this index.
Methods and materials
Cambridge post mastectomy radiotherapy index (C-PMRT index)
The C-PMRT index was constructed with scores (1–3) allocated
in each of four categories including the number of positive LN/LVI,
tumour size, margin status and tumour grade (Table 1). T3/T4 tu-
mour and/or positive deep margin and/orP4 positive LN resulted
in a score of 3 and patients were categorised as high (H) risk. 1–3
positive LN or a tumour size of 3–5 cm resulted in a score of 2. A
score of 1 was allocated for any of the following factors: LVI, tu-
mour size 2–3 cm or grade 3 tumour. Other patients with an aggre-
gate score P3 were categorised as intermediate (I) risk and <3 as
low (L) risk. PMRT was recommended for the H and I risk patients.Study population
All women treated by simple mastectomy for invasive breast
cancer from 1999 to 2009 at the Cambridge Breast Unit (CBU) were
included in this study. Patients were identiﬁed from the joint clin-
ical information service (JCIS) database and their paper and elec-
tronic hospital records were reviewed to obtain the relevant
information. Patients treated with mastectomy for local recurrence
after breast conserving surgery and non-radical surgery were ex-
cluded. All patients had either sentinel lymph node biopsy (SLNB)
or axillary clearance (if LN positive). Patients with microscopic ax-
illary disease were regarded as lymph node positive and given a
score of ‘‘2’’ on the C-PMRT index. Patients received adjuvant
chemotherapy according to local protocols and radiotherapy was
deferred until the completion of chemotherapy. Anthracycline-
based chemotherapy was predominantly used with additional
taxanes in selected cases. For patients receiving neo-adjuvant
chemotherapy, a decision for PMRT was made prior to starting
their chemotherapy, based on clinical, radiological and histopa-
thological features. These patients had SLNB prior to starting
neo-adjuvant chemotherapy. All ER positive patients also received
systemic endocrine therapy. Routine staging investigations were
carried out for patients with American Joint Committee on Cancer
stage 3 disease unless clinically indicated. LRR and systemic
relapse were treated as per the local policy.Radiotherapy treatment
Radiotherapy was delivered to the chest wall using tangents
with 6MV photons to a dose of 40 Gy in 15 fractions over 3 weeks.
0.5 cm tissue equivalent bolus for 7 of 15 fractions was applied toTable 1
Cambridge post-mastectomy radiotherapy (C-PMRT) index.
Score 3
Number of positive lymph nodes or LVI P4
Invasive tumour size >50 mm (T3) or T4
Excision margins Deep margin <1 mm or pec
Tumour grade –
LVI: lymphovascular invasion.
T4: tumour of any size with direct extension to the chest wall and/or to the skin (ulcerincrease the skin dose in most cases. If the skin was involved (T4
lesions), a full 1 cm bolus was applied to all 15 fractions. The radio-
therapy ﬁeld borders extended medially to the midline, laterally to
the mid axillary line, inferiorly to 1–2 cm below the level of the
inframammary fold and superiorly below the level of the supra-
sternal notch. A supraclavicular (SCF) radiation ﬁeld was only
added if there were P4 positive axillary LN. Axillary ﬁelds were
not routinely used unless there was evidence of macroscopic resid-
ual disease following axillary clearance. The internal mammary LN
chain was only irradiated if a positive internal mammary LN was
encountered during surgery or radiological imaging. The radiation
dose to the SCF and/or internal mammary LN chain was 40 Gy in 15
fractions over 3 weeks.Treatment endpoints and statistical analysis
All patients were followed up annually at the Cambridge Breast
Unit for a minimum of ﬁve years. The LRR, distant metastasis and
OS data was collected from patient’s medical records. The median
length of follow up was measured from the date of mastectomy to
the date of last follow up or date of death. Isolated LRR was deﬁned
as recurrent disease on the ipsilateral chest wall and/or regional
nodal ﬁelds without evidence of distant metastases for at least
3 months. The probabilities of LRR and OS were calculated by the
Kaplan–Meier method. The comparison between the L and I risk
group was performed using the log rank test with a two sided
t-test. All statistical analysis was done using STATA version 10.1
(STATA statistical software, release10; Stata Corporation, College
station, TX).Results
From 1999 to 2009, a total of 898 invasive breast cancers in 883
patients were treated by mastectomy at the CBU (H: 323, I: 231
and L: 344). 42/231 (18%) I risk group patients were LN negative,
but had an aggregate score P3 from other adverse prognostic
factors and were recommended PMRT. 35/344 (10%) LN positive
patients had an aggregate score <3 and were categorised into the
L risk group. The patients median age was 60 years (range
23–96 years). For patients with positive LN (486/898) on SLNB,
completion axillary clearance was recommended. The median
number of LN removed during axillary clearance was 16 (range
1–48). 130/898 (14.5%) patients received neo-adjuvant chemother-
apy and 220/898 (24.5%) received adjuvant chemotherapy.
Anthracycline ± taxanes based chemotherapy regimens were most
commonly used. Other patient characteristics are summarised in
Table 2.
At a median follow up of 5.2 years, 4.7% (42/898) developed
LRR. 5 year actuarial LRR rates were 6%, 2% and 2% for the H, I
and L risk groups, respectively (Fig. 1). Only 1.6% (14/898) devel-
oped isolated LRR (H risk n = 4, I risk n = 0 and L risk n = 10). The
most common sites of LRR were the chest wall (n = 22) and axilla
(n = 11) (Table 3). 5 year metastatic free rates were 71%, 83% and
95% for the H, I and L risk groups, respectively. 5 year actuarial2 1
1–3 LVI
30–50 mm 20–29 mm
toral muscle invasion - -
– Grade 3
ation or skin nodules).
Table 2
Summary of patient’s characteristics.
Characteristic Number of patients (%)
Tumour size
62 cm 373 (41.5)
2–5 cm 408 (45.5)
P5 cm 117 (13)
Tumour grade
Grade 1 76 (8.5)
Grade 2 416 (46.3)
Grade 3 380 (42.3)
Unknown 26 (2.9)
ER status
Positive 771 (85.9)
Negative 118 (13.1)
Unknown 9 (1.0)
Her2 status
Positive 104 (11.6)
Negative 421 (46.9)
Unknown/not done 373 (41.5)
Lympho-vascular invasion (LVI)
Absent 557 (62.1)
Present 267 (29.7)
Unknown 74 (8.2)
Lymph nodes status
0 412 (45.9)
1–3 301 (33.5)
4–9 118 (13.1)
P10 67 (7.5)
Deep margins clear
No 23 (2.6)
Yes 871 (97)
Unknown 4 (0.4)
Systemic chemotherapy
No 534 (59.5)
Neo-adjuvant 130 (14.5)
Adjuvant 220 (24.5)
Unknown 14 (1.5)
Fig. 1. The loco-regional recurrence rates within the low (L), intermediate (I) and
high (H) risk group.
Table 3
Sites of loco-regional recurrence (LRR).
Site LRR (%) Risk group Isolated LRR
(%)
Risk
group
Chest wall 22
(52.4%)
H: 10, I: 3 and
L: 9
9 (64.3%) H: 1 and
L: 8
Axilla LN 11
(26.2%)
H: 9 and L: 2 4 (28.6%) H: 2 and
L: 2
SCF LN 5
(11.9%)
H: 2 and I: 3 1 (7.1%) H: 1
IMC LN 1 (2.4%) I: 1 0 –
Chest wall + regional
nodes
3 (7.1%) H: 3 0 –
Total patients 42 14
LN: lymph nodes.
IMC: internal mammary chain.
H: high risk group.
I: intermediate risk group.
L: low risk group.
Fig. 2. Five-year overall survival rates within the low (L), intermediate (I) and high
(H) risk group.
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respectively (Fig. 2).Compliance to C-PMRT index
305/323 (94%) H risk category cases and 185/231 (80%) I risk
category cases received PMRT. The reasons for non-compliance to
the index were: old age (25 cases), medical co-morbidities (9cases), metastatic disease/death pre-radiotherapy (7 cases), patient
refusal (5 cases), wound healing (2 cases) and unknown (16 cases).
27/344 (8%) L risk category cases had PMRT as recommended by
the multi-disciplinary team (MDT). The reasons for recommending
PMRT were multi-focal disease (11 cases), young age (6 cases), ER
negative tumour (3 cases), limited axillary dissection (1 case),
patient request (1 case) and unknown (5 cases).Discussion
PMRT lowers the risk of LRR and for some patients, improves
overall survival [17]. The international consensus recommends
PMRT for patients with T3/T4 tumours orP4 positive LN. The Dan-
ish Breast Cancer Cooperative Group (DBCCG) trials 82b and 82c
and the British Columbia trial concluded that PMRT improves over-
all survival irrespective of the number of positive LN [1–3]. How-
ever, these trials were criticised for using less intensive
chemotherapy and limited axillary dissection. The Early Breast
Cancer Trialists’ Collaborative Group (EBCTCG) overview also indi-
cated similar beneﬁts of PMRT for patients with 1–3 andP4 posi-
tive LN [17]. However, data on LN involvement was not available
for more than half the patients and most of the patients included
in the meta-analysis were from the DBCCG trials. Overgaard et al.
464 Patient selection for post-mastectomy RT[18] presented a subgroup analysis of the DBCCG trials, only
including LN positive patients who met the criteria of having 8
or more LN removed and showed similar survival beneﬁt of PMRT
in patients with 1–3 and P4 positive LN. As a result of this, some
international guidelines now suggest that PMRT should be consid-
ered for women with 1–3 positive LN [19,20].
Loco-regional and/or systemic cancer recurrence are both dev-
astating for patients and the overall treatment strategy should in-
clude both optimal local and systemic therapy. On-line tools like
Adjuvant online and Predict take into account several prognostic
factors to aid selection of patients for systemic therapy [21,22].
Apart from LN status, a number of other prognostic factors for
LRR have been reported, with the risk of LRR increasing proportion-
ally to the number of adverse prognostic factors [10,12,13]. Jagsi et
al. [10] reported tumour size >2 cm, LVI, margins <2 mm and pre-
menopausal status as independent prognostic factors for LRR in LN
negative patients treated with mastectomy. The 10 year LRR was
10% for those with one risk factor, 18% with two risk factors and
40% with three risk factors without PMRT. Similarly, a study from
Massachusetts reported tumour size P2 cm, positive margins,
young age, no systemic therapy and LVI as poor prognostic factors
for LRR in LN negative patients, with a 20% risk of LRR without
PMRT amongst patients with three or more prognostic factors [11].
The CBU developed the C-PMRT index in 1999, based on the
principle that along with LN status, other prognostic factors for
LRR should also be considered for selecting PMRT patients. The
published literature at that time supported that the risk of LRR
without adjuvant radiotherapy could beP20% for the H and I risk
patients and hence these patients were considered for PMRT. The
5 year LRR in this study is excellent for all three risk groups (H:
6%, I: 2%, L: 2%) with no signiﬁcant difference between the I and
L risk group patients (p = 0.95 on the log rank test). The incidence
of LRR is falling, which can be attributed to the improvement in
imaging, histopathology assessment and surgery, more effective
systemic therapy and better RT techniques [23]. We hypothesise
that the I risk group LRR rates could have been reduced to that
of the L risk group in this study by the addition of PMRT.
Unlike the DBCCG trials and the British Columbia trial, RT was
limited to the chest wall alone in this series, except for patients
with P4 positive LN and/or internal mammary LN. Isolated nodal
recurrences were uncommon in this series and the most common
site of isolated LRR was the chest wall (see Table 3). These results
are in keeping with the other reports which suggest that for pa-
tients with adequate axillary assessment, the most common site
of LRR is the chest wall [10,11,24,25].Table 4
LRR after sub-classiﬁcation of patients based on molecular proﬁling.
Loco-regional recurrence rates
PMRT: yes (number of
patients)
PMRT: no (number of
patients)
Er+ve/Her2ve
(n = 369)
3.1% (225) 5.5% (144)
Er+ve/Her2+ve
(n = 64)
6.2% (48) 6.2% (16)
Erve/Her2+ve
(n = 40)
6.9% (29) 0% (11)
Erve/Her2ve
(n = 50)
9.1% (33) 0% (17)
Er: oestrogen receptor.
Her-2, human epidermal growth receptor-2.Role of PMRT with systemic therapy
The use of contemporary systemic therapies also reduces the
risk of LRR and one can argue that the risk of LRR for the I risk
group without RT will now also be lower (10%) [26]. Many clini-
cians however will still consider PMRT for a LRR risk of 10%. In
addition, if one believes that the ratio between prevention of LRR
and breast cancer death is four to one [17], the addition of PMRT
for the I risk group may equate to an improvement in OS by
2–3%. It is also plausible that the ratio between prevention of
LRR and breast cancer death may not be constant across all patient
groups. Patients with P4 positive LN are more likely to harbour
micro-metastatic disease than those with 1–3 positive LN or LN
negative patients with other adverse prognostic features. The
improvement in loco-regional control with PMRT in the I risk
group is more likely to translate into survival beneﬁt as the com-
peting risk of dying from pre-existing micro-metastatic disease is
lower. This hypothesis has been supported in the EBCTCG overview
and other retrospective studies [17,27,28]. In the EBCTCG over-
view, PMRT reduced the 5 year LRR by 11.6% (15.5% versus 4%)and 15 years breast cancer speciﬁc mortality by 4.4% (47.7% versus
43.3%) amongst women with 1–3 positive LN. In contrast, for
women with P4 positive LN, 5 year LRR was reduced by 14.8%
(26.3% versus 11.6%) but the 15 year breast speciﬁc mortality
was only reduced by 2.3% (70.3% versus 68%). Kyndi et al. [27]
divided 1000 patients from the DBCCG trials 82b and 82c into three
sub-groups of good, intermediate and poor prognosis based on
their local recurrence risk probability. For the ‘‘poor’’ prognosis
group, PMRT reduced the local recurrence probability by 36% but
this large reduction in local recurrence failed to translate into abso-
lute reduction in breast cancer mortality. In contrast, PMRT re-
duced the local recurrence probability by 21% and 11% in the
‘‘intermediate’’ and ‘‘good’’ prognosis group respectively, and this
translated into an 11% reduction in breast cancer mortality in both
groups. Similar results were shown in the combined analysis of the
EORTC 10801, 10854 and 10902 trials, with PMRT improving loco-
regional control for both 1–3 andP4 positive LN patients, with the
survival beneﬁt amongst patients with 1–3 positive LN alone [28].
Contemporary systemic therapy can more successfully eradicate
distant micro-metastatic disease and is more likely to compliment
PMRT, than being competitive.Molecular predictors of loco-regional recurrence (LRR)
Apart from clinical variables discussed above, molecular mark-
ers including oestrogen receptor, Her-2 and Ki-67 status have also
been associated with risk of LRR post mastectomy [29–31]. Based
on these molecular markers, patients have been sub-classiﬁed as:
luminal A/B, Her-2 enriched and basal phenotype with the risk of
LRR highest amongst Her-2 enriched and basal phenotype tumours
[29]. Similarly, Voduc et al. [32] completed a semi quantitative
analysis of oestrogen receptor, progesterone receptor, Ki-67, Her-
2, epidermal growth factor receptor and cytokeratin 5/6 on 2985
patients and classiﬁed patients into the following categories: lumi-
nal A, luminal B, luminal-Her-2, Her-2 enriched, basal type and tri-
ple negative phenotype-non basal. At a median follow up of
12 years after mastectomy, patients with luminal B, luminal Her-
2, Her-2 enriched and basal phenotype were found to be at the
higher risk of LRR. Mamounas et al. [33] showed a strong associa-
tion between the 21-gene OncotypeDX recurrence score and risk of
LRR (p < 0.001) amongst node negative, oestrogen receptor positive
breast cancer patients treated with tamoxifen. However, most of
the studies using molecular proﬁling for LRR were conducted in
the pre-trastuzumab era and it is possible that the use of adjuvant
trastuzumab will negate Her-2 overexpression as a risk factor for
LRR [34].
In the current study, both oestrogen receptor and Her-2 pheno-
type were available for 523 patients and most patients with Her-2
overexpression received adjuvant trastuzumab. As an exploratory
analysis, these patients were subcategorised as: Er+ve/Her2ve,
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were analysed at ﬁve years (Table 4). For ‘‘High’’ and ‘‘Intermedi-
ate’’ risk patients who received PMRT, the LRR rates were higher
amongst ERve and Her-2 overexpressing tumours. On the con-
trary, for patients with favourable clinical variables (‘‘Low’’ risk
group), this did not hold true. It is possible that these results can
be explained by chance as there were small numbers of patients
in the Low risk group. However, it is also possible that these results
are real and molecular proﬁling of tumours provide additional
information on LRR risk when used in conjunction with other clin-
ical variables including tumour size, lymph node status and LVI.
This hypothesis is supported by the large study of 2985 patients,
where along with tumour molecular phenotype; large tumour size,
positive lymph nodes and high grade tumour were reported as
independent predictors of LRR [32]. The European SUPREMO trial
sub-study TRANS-SUPREMO is collecting tissue block for patients
who have developed recurrence and will provide more information
on the role of molecular proﬁling in the future [16].Late side effects with PMRT
Clinicians may have concerns that the late cardiac/pulmonary
toxicity and risk of secondary cancer from RT may counterbalance
the potential beneﬁt of PMRT in the I risk group. However, with
improvement in RT techniques and use of CT planning, irradiation
dose to the healthy normal tissue is decreasing [35]. The risk of car-
diac- and pulmonary-related mortality and secondary cancer con-
tinues to decrease and may only be slightly higher as compared to
the non-RT patients in the era of modern RT [36,37]. The interac-
tion between cardiotoxic agents (anthracycline and trastuzumab)
and RT remains to be elucidated. Another important adverse effect
of PMRT is the increased risk of capsular contracture amongst pa-
tients with implant-based reconstruction [38]. Hence, the risks and
beneﬁts of PMRT should be individually discussed with patients. In
this series, only four I risk patients declined PMRT secondary to
implant based reconstruction.Limitations
This study reports on the patients outcome stratiﬁed according
to the C-PMRT index over a 10 year period and like any other ret-
rospective study is prone to stage migration. Ideally, the variables
for a prognostic index should be based on multivariate analysis
from a RCT. However, with paucity of trial data, a more pragmatic
approach was taken and the C-PMRT index was generated using
published literature on prognostic factors for LRR. As there is insuf-
ﬁcient evidence to rank individual risk factors in order of their im-
pact on LRR, an arbitrary weighting was given to the variables. The
tumour grade and LVI were identiﬁed as risk factors from retro-
spective series and given a low weighting (score = 1). 1–3 positive
LN was given a higher weighting (score = 2) based on the results of
the RCTs [1,2]. Increment in tumour size has been associated with
higher risk of LRR [24]. So tumour size 2–3 cm was given low
weighting (score = 1) and tumour size 3–5 cm was given a higher
weighting (score = 2). Other possible prognostic factors for LRR
including young age and ER status were not included in the index,
though it inﬂuenced the MDT recommendations for some patients.
We accept that a pragmatic tool like C-PMRT index will beneﬁt
from external validation and require adaptation as new informa-
tion on predictive and prognostic markers of LRR becomes
available [32].
The C-PMRT index was designed for patients treated with adju-
vant systemic therapy. However, there is little consensus on the
role of PMRT after primary chemotherapy. Patients who received
primary chemotherapy are also included in this report as the same
index was used for patient selection. The decisions on PMRT weremade prior to patients starting chemotherapy using all available
information. A repeat analysis after excluding patients with
primary chemotherapy show similar results (appendix: LRR Fig. 3
and OS Fig. 4).
Conclusions
Apart from LN status and tumour size, other adverse prognostic
factors should also be considered in selecting patients for PMRT.
The SUPREMO trial will provide level I evidence on the role of
PMRT for intermediate risk patients in the future. The molecular
proﬁling of tumour is likely to complement clinical variables when
selecting patients for PMRT and merits further investigation.
Meanwhile, based on the available evidence today, it is reasonable
to consider a practical tool like the C-PMRT index for patient’s
selection outside the framework of a clinical trial. This pragmatic
tool will beneﬁt from further validation.
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